Organoids and spheroids are no longer academic experiments. For complex therapeutic modalities they are the only practical way to generate predictive data.
mRNA-based therapies, gene therapy and next-generation biologics require test systems that reproduce the three-dimensional architecture of the target tissue.
2D models under-estimate permeability and immune response. Organoids derived from primary cells deliver predictability — at an experimental complexity most labs have not mastered.
We build and validate bespoke 3D models for each modality, with STR quality controls and continuous phenotype monitoring.